SCHEDULE 13G/A: Neil Kumar Discloses 5.41% Beneficial Ownership in BridgeBio Pharma

Dr. Neil Kumar, a key figure, has disclosed a beneficial ownership of 5.41% in BridgeBio Pharma, Inc., totaling 10,466,712 shares as of December 31, 2024.

Summary

• Dr. Neil Kumar, the reporting person, beneficially owns 10,466,712 shares of BridgeBio Pharma, Inc. Common Stock.
• This ownership represents 5.41% of the company's outstanding Common Stock as of December 31, 2024.
• The total shares beneficially owned include 211,718 shares held directly by Dr. Kumar, 3,505,322 shares from exercisable stock options within 60 days, and 55,539 shares from restricted stock units vesting within 60 days.
• Additionally, 5,698,447 shares are held by the Kumar Haldea Revocable Trust, and 995,686 shares by the Kumar Haldea Family Irrevocable Trust, where Dr. Kumar is a co-trustee.
• Dr. Kumar holds sole voting and dispositive power over 3,772,579 shares and shared voting and dispositive power over 6,694,133 shares.
• The percentage ownership calculation is based on 190,044,473 shares of Common Stock outstanding as of December 31, 2024, plus Dr. Kumar's exercisable options and vesting RSUs.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it indicates a significant and continued ownership stake by a key individual, which can be viewed favorably by investors as a sign of confidence and alignment of interests. However, it is a factual disclosure and not a performance report.

Positives

• The disclosure indicates a significant and continued beneficial ownership stake by a key individual (Neil Kumar), which can signal alignment of interests with shareholders.

Negatives

• This Schedule 13G filing is a factual disclosure of beneficial ownership and does not inherently contain negative financial or operational information.

Risks

• This Schedule 13G filing is a factual disclosure of beneficial ownership and does not inherently contain specific risks related to the company's operations or financial health.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

This filing is a standard regulatory disclosure of beneficial ownership by an individual, common in the biotechnology sector where founders and key executives often retain significant stakes. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: The disclosure of a significant beneficial ownership by Dr. Neil Kumar may reassure shareholders about management's alignment with long-term company performance and shareholder value.

Key Dates

Recommendation

Keywords

BridgeBio Pharma, Neil Kumar, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Stock Options, Restricted Stock Units, Insider Ownership, Biotechnology